Collegium Pharmaceutical (COLL) Invested Capital (2014 - 2026)

Collegium Pharmaceutical has reported Invested Capital for 13 years, with the latest figure at $1.2 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 42.49% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 42.49% increase from a year earlier, with the FY2025 full-year figure at $872.8 million, up 3.39% from the prior year.
• Invested Capital was $1.2 billion for Q2 2026 at Collegium Pharmaceutical, up from $876.8 million in the prior quarter.
• The five-year high for Invested Capital was $1.2 billion in Q2 2026, with the low at $532.8 million in Q2 2024.
• Average Invested Capital over 5 years is $779.9 million, with a median of $810.4 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Invested Capital soared 161.12% in 2022, then retreated 23.24% in 2024.
• Over 5 years, Invested Capital stood at $754.9 million in 2022, then decreased by 20.46% to $600.5 million in 2023, then surged by 40.58% to $844.2 million in 2024, then climbed by 3.39% to $872.8 million in 2025, then soared by 33.45% to $1.2 billion in 2026.
• The last three Invested Capital figures came in at $1.2 billion (Q2 2026), $876.8 million (Q1 2026), and $872.8 million (Q4 2025), per Business Quant data.